Abstract
Cell cycle ckeckpoints are activated in response to DNA damage. Their role consists in blocking the cell cycle to allow time for DNA repair. The activity of the G1 checkpoint is dependent on the p53 protein. In more than 50% of human tumor cells, the p53 gene is mutated. In the p53 mutated cells, the G1 checkpoint is lacking. In these cells, only the G2 checkpoint, although weaker than in healthy cells, provides cancer cells with the opportunity to repair the DNA after damage. Therefore, combining a G2 checkpoint inhibitor with a DNA damaging agent should force, selectively cancer cells, into a premature and lethal mitosis, due to an accumulation of DNA lesions. Among the regulators of the G2 checkpoint, Checkpoint 1 kinase (Chk1) plays a major role. A widespread interest has been recently devoted to the discovery of Chk1 inhibitors as potential useful compounds to enhance the antitumor efficiency of DNA damaging agents. This review article will summarize: (i) the chemical structures of the novel Chk1 inhibitors reported in the recent patents; (ii) their inhibitory activity towards Chk1; (iii) their effects on tumor cells in combination with DNA damaging agents; and (iv) the in vivo results on animal models.
Keywords: G2 checkpoint, Chk1 inhibitors, anticancer agents, cell cycle, benzimidazole quinolines, diazepinoindole derivatives, diarylurea derivatives, aminopyrazoles
Recent Patents on Anti-Cancer Drug Discovery
Title: Novel Checkpoint 1 Inhibitors
Volume: 1 Issue: 1
Author(s): Michelle Prudhomme
Affiliation:
Keywords: G2 checkpoint, Chk1 inhibitors, anticancer agents, cell cycle, benzimidazole quinolines, diazepinoindole derivatives, diarylurea derivatives, aminopyrazoles
Abstract: Cell cycle ckeckpoints are activated in response to DNA damage. Their role consists in blocking the cell cycle to allow time for DNA repair. The activity of the G1 checkpoint is dependent on the p53 protein. In more than 50% of human tumor cells, the p53 gene is mutated. In the p53 mutated cells, the G1 checkpoint is lacking. In these cells, only the G2 checkpoint, although weaker than in healthy cells, provides cancer cells with the opportunity to repair the DNA after damage. Therefore, combining a G2 checkpoint inhibitor with a DNA damaging agent should force, selectively cancer cells, into a premature and lethal mitosis, due to an accumulation of DNA lesions. Among the regulators of the G2 checkpoint, Checkpoint 1 kinase (Chk1) plays a major role. A widespread interest has been recently devoted to the discovery of Chk1 inhibitors as potential useful compounds to enhance the antitumor efficiency of DNA damaging agents. This review article will summarize: (i) the chemical structures of the novel Chk1 inhibitors reported in the recent patents; (ii) their inhibitory activity towards Chk1; (iii) their effects on tumor cells in combination with DNA damaging agents; and (iv) the in vivo results on animal models.
Export Options
About this article
Cite this article as:
Prudhomme Michelle, Novel Checkpoint 1 Inhibitors, Recent Patents on Anti-Cancer Drug Discovery 2006; 1 (1) . https://dx.doi.org/10.2174/157489206775246520
DOI https://dx.doi.org/10.2174/157489206775246520 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Paraneoplastic Pemphigus: Autoimmune-Cancer Nexus in the Skin
Anti-Cancer Agents in Medicinal Chemistry Predictors and Clinical Implications of HPV Reservoire Districts for Genital Tract Disease
Current Pharmaceutical Design Immunity to Bacterial Infections
Current Immunology Reviews (Discontinued) Characterization of the Lymphotropic Amplicons-6 and Tamplicon-7 Vectors Derived from HHV-6 and HHV-7
Current Gene Therapy Anti-cancer Research on Arnebiae radix-derived Naphthoquinone in Recent Five Years
Recent Patents on Anti-Cancer Drug Discovery Pathology of the HPV-associated Oropharyngeal Carcinoma
Current Cancer Therapy Reviews Mechanism of Action and Therapeutic Potential of Novel Adamantyl Retinoid-Related Molecules
Current Cancer Therapy Reviews LHRH-Targeted Drug Delivery Systems for Cancer Therapy
Mini-Reviews in Medicinal Chemistry Involvement of Cysteine Proteases in Cancer
Current Medicinal Chemistry Nanoparticle Engineering Enhances Anticancer Efficacy of Andrographolide in MCF-7 Cells and Mice Bearing EAC
Current Pharmaceutical Biotechnology Cancer Prevention with Promising Natural Products: Mechanisms of Action and Molecular Targets
Anti-Cancer Agents in Medicinal Chemistry Mast Cells as Target in Cancer Therapy
Current Pharmaceutical Design Pharmaceutical Perspectives of HECT-TYPE Ubiquitin Ligase Smurf1
Current Pharmaceutical Design Antioxidant Properties of Fractions for Unripe Fruits of Capsicum annuum L. var. Conoides
Anti-Cancer Agents in Medicinal Chemistry Research Advances in the Treatment of Melanoma by Treat Melanoma
Current Topics in Medicinal Chemistry Molecular Signature of HPV-Induced Carcinogenesis: pRb, p53 and Gene Expression Profiling
Current Genomics Xanthohumol: A Metabolite with Promising Anti-Neoplastic Potential
Anti-Cancer Agents in Medicinal Chemistry Genistein Induces Alterations of Epigenetic Modulatory Signatures in Human Cervical Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Impact of RET Screening on the Management of Multiple Endocrine Neoplasia Type 2A: 10 Years Experience and Follow-Up in Three Families
Endocrine, Metabolic & Immune Disorders - Drug Targets Himalayan Plants as a Source of Anti-Cancer Agents: A Review
The Natural Products Journal